Radius Recycling, Inc. (RDUS)
(Delayed Data from NSDQ)
$18.48 USD
-0.06 (-0.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $18.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.48 USD
-0.06 (-0.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $18.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Will Radius Health (RDUS) Disappoint this Earnings Season?
by Zacks Equity Research
Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.
Why Did Radius Health (RDUS) Stock Plummet Today?
by Ryan McQueeney
Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.
Radius Health (RDUS) Looks Good: Stock Adds 10.5% in Session
by Zacks Equity Research
Radius Health, Inc. (RDUS) shares jumped above 10% in the last trading session.
Radius (RDUS) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.
Why Is Radius Health (RDUS) Down 2.7% Since the Last Earnings Report?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health Osteoporosis Drug Positive in Phase III Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.
Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.
Radius Health (RDUS) Q1 Earnings: What's in Store?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.
Radius Health (RDUS) Down 11.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health (RDUS) Posts Wider Loss in Q4
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.